340B Insight provides members and supporters of 340B Health with timely updates and discussions about the 340B drug pricing program. The podcast helps listeners stay current with and learn more about 340B to help them serve their patients and communities and remain compliant. We publish new episodes twice a month, with news reports and in-depth interviews with leading health care practitioners, policy and legal experts, public policymakers, and our expert staff.
Addressing Payer-Mandated White Bagging of Drugs
This week, we are joined by Kyle Robb, a state policy and advocacy associate for the American Society of Health System Pharmacists (ASHP). Kyle discusses the rise in payer-mandated white bagging, why hospital pharmacists are concerned about the trend, and how health providers and patients are affected by this model. Before the interview, our news update covers the critical step the Health Resources & Services Administration (HRSA) recently took to enforce the law on drug companies that have refused discounts to 340B covered entities when drugs are dispensed at contract pharmacies.
Drug Company 340B Discount Refusals Harm Patients
It is the one-year anniversary of 340B Insight, and this week we are joined by Anne Webster, a nurse practitioner for UnityPoint Health Methodist in Peoria, Ill. Anne discusses how drug company restrictions on 340B pricing on drugs dispensed at community pharmacies have directly affected her patients living with diabetes and their ability to access the insulin and other medications they need to manage their conditions. **Please note that the episode was recorded prior to the Health Resources & Services Administration (HRSA) announcing on May 17, 2021, that drug companies refusing 340B discounts to safety-net hospitals and providers on drugs dispensed at community pharmacies are in violation of the law and that they must offer 340B pricing and pay refunds. We will discuss this news in future episodes.**
How 340B Fits Into the Drug Pricing World
This week we are joined by Sean Dickson, director of health policy for West Health Policy Center. Sean is an expert on the U.S drug system and focuses on policies that reduce prescription drug costs. Sean discusses why drug prices are so high, his research on how 340B fits into the drug pricing policy conversation and affects overall drug pricing, and what approaches policymakers can take to curb high drug prices. Before the interview, our news update shares developments on drug pricing bills recently introduced in Congress and how a group of hospital and pharmacy organizations, including 340B Health, wrote to HHS Secretary Xavier Becerra about what the department can do to stop drug manufacturers from refusing 340B discounts on drugs dispensed at community pharmacies.
Maureen Testoni on Top 340B Developments
This week we are joined by Maureen Testoni, 340B Health’s president and CEO. Maureen provides her expert analysis on the top 340B developments from the first quarter of 2021. The conversation includes the latest on drug manufacturers denying 340B discounts on drugs dispensed at community pharmacies, attempts to turn 340B into a rebate program, and payers and pharmacy benefit managers making mandatory changes to their claims processes. Maureen also shares positive recent developments on advocating for 340B.
340B in the World of Cancer Treatment
April is National Cancer Control Month, and this week we are joined by Dr. Gerold Bepler, president and CEO at the Barbara Ann Karmanos Cancer Institute in Detroit. Dr. Bepler discusses the unique role cancer centers play in preventing and treating cancer, the importance of 340B to Karmanos and its patients, how Karmanos is addressing racial and ethnic disparities in cancer treatment, and the partnership it has formed to expand access to cancer research and treatment in rural communities. Before the interview, we recap 340B Health’s recent virtual Hill Day.
How State Policy Affects 340B
This week we are joined by Amanda Sellers Smith, the assistant counsel for 340B Health. While 340B is a federal program, it is intertwined with Medicaid and states’ oversight of the health care marketplace. Amanda discusses how states are protecting 340B covered entities from discriminatory reimbursement, why changes to state Medicaid policy can affect 340B in multiple ways, and how listeners can advocate for 340B at the state level. Before the interview with Amanda, we recap the results of the newly released 340B Health annual survey of 340B hospitals.
Thank you for providing a great resource!
It’s About Time!
I love it. I am so glad 340B Health jumped on this. Turnkey has had it on our “idea” list, but feel 340B Health is best suited to take this on. Love the concept and information.